Jazz Pharmaceuticals (HAM:J7Z) Cyclically Adjusted Book per Share: €52.63 (As of Mar. 2026)


HAM:J7Z Jazz Pharmaceuticals PLC HAM:J7Z
73 GF Score
Price €209.50
GF Value €127.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Cyclically Adjusted Book per Share?

Jazz Pharmaceuticals HAM:J7Z +4.91% 73 Cyclically Adjusted Book per Share is €52.63 as of Mar. 2026. GuruFocus rates HAM:J7Z with a GF Score™ of 73/100 and a GF Value™ of €127.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €62.527. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €52.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jazz Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 8.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 9.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 13.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Jazz Pharmaceuticals was 31.50% per year. The lowest was 9.80% per year. And the median was 24.60% per year.

As of today (2026-07-01), Jazz Pharmaceuticals's current stock price is €209.50. Jazz Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €52.63. Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 3.98.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Jazz Pharmaceuticals was 14.71. The lowest was 1.71. And the median was 3.93.


Jazz Pharmaceuticals  (HAM:J7Z) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=209.50/52.63
=3.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Jazz Pharmaceuticals was 14.71. The lowest was 1.71. And the median was 3.93.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Jazz Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Jazz Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Cyclically Adjusted Book per Share Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 51.81

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 51.81 52.63

HAM:J7Z vs BBIO, EXEL, IONS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


HAM:J7Z
73GF Score
Jazz Pharmaceuticals PLC HAM:J7Z
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jazz Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=62.527/125.8201*125.8201
=62.527

Current CPI (Mar. 2026) = 125.8201.

Jazz Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 24.903 101.072 31.001
201609 25.529 100.274 32.033
201612 29.751 99.676 37.554
201703 30.923 100.374 38.762
201706 32.599 100.673 40.742
201709 34.558 100.474 43.276
201712 38.275 100.075 48.122
201803 37.672 100.573 47.129
201806 40.747 101.072 50.724
201809 43.009 101.371 53.382
201812 42.150 100.773 52.627
201903 42.466 101.670 52.553
201906 46.628 102.168 57.422
201909 48.984 102.268 60.265
201912 49.873 102.068 61.479
202003 45.905 102.367 56.422
202006 50.309 101.769 62.198
202009 51.577 101.072 64.206
202012 53.556 101.072 66.670
202103 56.091 102.367 68.942
202106 56.110 103.364 68.300
202109 54.541 104.859 65.444
202112 56.937 106.653 67.169
202203 52.640 109.245 60.627
202206 48.352 112.779 53.943
202209 44.087 113.504 48.871
202212 46.081 115.436 50.226
202303 48.681 117.609 52.080
202306 51.330 119.662 53.972
202309 51.943 120.749 54.125
202312 55.045 120.749 57.357
202403 53.956 120.990 56.110
202406 56.611 122.318 58.232
202409 62.176 121.594 64.337
202412 64.481 122.439 66.262
202503 62.668 123.405 63.894
202506 52.992 124.492 53.557
202509 55.533 124.854 55.963
202512 60.032 125.820 60.032
202603 62.527 125.820 62.527

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €52.63 mean?
Jazz Pharmaceuticals (HAM:J7Z) has a Cyclically Adjusted Book per Share of €52.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Jazz Pharmaceuticals' current Cyclically Adjusted Book per Share is €52.63. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Cyclically Adjusted Book per Share compare to BBIO and EXEL?
Jazz Pharmaceuticals' Cyclically Adjusted Book per Share of €52.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Cyclically Adjusted Book per Share is €52.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (HAM:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €127.01, compared to a current price of €209.50 — trading 64.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €52.63. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Jazz Pharmaceuticals (HAM:J7Z), the current Cyclically Adjusted Book per Share is €52.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (HAM:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €209.50 is trading 64.9% above its estimated GF Value™ of €127.01. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HAM:J7Z:

  • Cyclically Adjusted Book per Share: €52.63
  • GF Value™: €127.01 vs. price of €209.50 (64.9% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the HAM:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for HAM:J7Z

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€209.50
Price
€127.01
GF Value